Close Menu
NEW YORK – Qiagen said on Friday that it will receive $598,000 in funding from the US Department of Health and Human Services to develop a version of its QiaStat-Dx Respiratory Panel that will be able to differentiate the novel coronavirus SARS-CoV-2 from 21 other common respiratory pathogens.
The funding is being provided through a streamlined process called an easy broad agency announcement (EZ-BAA), which is managed by the HHS Office of the Assistant Secretary for Preparedness and Response's (ASPR's) Biomedical Advanced Research and Development Authority (BARDA).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.